These data suggest that wild-type Kras acts to suppress the penetrance of mutant oncogenic KrasG12D, thus dampening MAPK signalling and contributing to therapeutic resistance in Kras mutant tumours, a key clinical problem. The gene discussed is KRAS; the disease is neoplasm.